Lunai Bioworks Inc. (LNAI), an AI-driven life sciences company, on Monday announced a $20 million preferred equity issuance to acquire intellectual property to strengthen its platform for developing drug delivery to the central nervous system.
The intellectual property (IP), acquired from to counterparties, will allow for the expansion of the company's central nervous system (CNS) platform, addressing a limitation in drug delivery that crosses the blood-brain-barrier (BBB) for effective treatment of neurological indications like Alzheimer's disease.
The acquired assets will be merged into the company's subsidiary, Lunai Bioworks IP Inc. On May 1, 2026, Lunai issued Series B Preferred Stock worth an aggregate value of $20 million to the Holders, to facilitate the merger.
The acquired IP is expected to contribute to the company's Augusta platform, which stratifies patients according to underlying biological drivers, and will also strengthen biodefense initiatives, like the Pathfinder program.
LNAI is currently trading at $0.36, up 14.72%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.